{"brief_title": "Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.", "brief_summary": "To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with Kaposi's sarcoma who have previously received systemic chemotherapy with or without an anthracycline.", "detailed_description": "Patients receive DOX-SL every 3 weeks for up to 20 cycles.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Doxorubicin hydrochloride (liposomal)", "criteria": "Inclusion Criteria Patients must have: - AIDS-related Kaposi's sarcoma that requires systemic chemotherapy. - EITHER a medical indication for continuation of DOX-SL following treatment on another DOX-SL protocol, OR no remaining treatment options other than DOX-SL. Prior Medication: Allowed: - Prior anthracyclines. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Cardiac ejection fraction < 50 percent or clinically significant cardiac disease. - Eligibility for a Liposomal Technology comparative protocol. Concurrent Medication: Excluded: - Other cytotoxic chemotherapy. Patients with the following prior condition are excluded: History of idiosyncratic or allergic reaction to anthracyclines. Prior Medication: Excluded: - Chemotherapy within the past 3 weeks.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002147.xml"}